Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of Adstiladrin alone or with gemcitabine + docetaxel or Keytruda in BCG-unresponsive NMIBC
2024-512177-27-01Phase 3Authorised
- Sponsor
- Ferring Pharmaceuticals
- Start
- Sep 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial in non-muscle-invasive bladder cancer (NMIBC) and urothelial carcinoma in situ (CIS) comparing Adstiladrin monotherapy, Adstiladrin + gemcitabine + docetaxel and Adstiladrin + Keytruda (3 arms). Primary endpoint: Complete response. Planned start Sep 2025; status: authorised.
02
Drugs
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)urothelial carcinoma in situ (CIS)
Beyond the preview
Go deeper on 2024-512177-27-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512177-27-01.